FDA Warns of Serious Side Effects Associated with Fluoroquinolone Antibacterial Drugs

May 16, 2016

On Thursday, May 12th, the FDA issued a warning regarding fluoroquinolone antibacterial drugs, stating that the associated side effects “generally outweigh the benefits for patients with sinusitis, bronchitis, and uncomplicated urinary tract infections who have other treatment options.”  FDA has stated that patients with these conditions should only use fluoroquinolone when there is no alternative treatment option.

According to the Agency, a safety review of the product has shown that the use of fluoroquinolone is “associated with disabling and potentially permanent serious side effects that can occur together.”  The potential side effects are said to involve the tendons, muscles, joints, nerves, and central nervous system.

In response to the recently discovered safety concerns, the FDA is requiring drug makers to update drug labels and Medication Guides for all fluoroquinolone products to include this new information.  In its Drug Safety Communication, FDA stated that the Agency is continuing to investigate safety issues with the products and additional information will be provided as it becomes available.

In the meantime, FDA is advising health care professionals to stop fluoroquinolone treatment immediately if a patient experiences serious side effect.  In addition, patients taking fluoroquinolone products should contact their physician immediately upon experiencing any serious side effects.

Agency Alerts General Regulatory

February 4, 2016

FDA Partners with Commonwealth Informatics to Build Drug Safety Analysis Platform

On January 28, 2016, the FDA and Commonwealth Informatics entered into a two-year agreement where they will work together to develop a platform to help the Agency assess drug safety data. The...

Read the Full Article
Agency Alerts General Regulatory

November 27, 2018

FDA Takes Steps to Promote Digital Tools for Prescription Drugs

On Tuesday, November 20th, FDA announced the establishment of a public docket to solicit comments and feedback on a proposed framework regarding the regulation of prescription drug-use-related...

Read the Full Article
Quality & Compliance GMP

May 31, 2017

FDA Warns Drug Manufacturers of Recalls due to BCC Contamination

On Monday, May 22nd, the FDA issued a warning for drug manufacturers regarding the contamination risk posed by Burkholderia cepacia complex (BCC).  According to FDA’s warning, “BCC and other...

Read the Full Article